An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.

This study aimed to evaluate the safety and reactogenicity of two intramuscular injections of two different dosages of an investigational clade B HIV vaccine.

Start Date01 Oct 2010

Sponsor / Collaborator

Institut Pasteur

100 Clinical Results associated with HIV vaccine(NuGenerex Immuno-Oncology, Inc.)

100 Translational Medicine associated with HIV vaccine(NuGenerex Immuno-Oncology, Inc.)

100 Patents (Medical) associated with HIV vaccine(NuGenerex Immuno-Oncology, Inc.)

Literatures (Medical) associated with HIV vaccine(NuGenerex Immuno-Oncology, Inc.)

01 Nov 2021·Journal of Applied PhysiologyQ3 · MEDICINE

Aerobic exercise with blood flow restriction causes local and systemic hypoalgesia and increases circulating opioid and endocannabinoid levels

Q3 · MEDICINE

Article

Author: Grant, Ian ; Patterson, Stephen David ; Hughes, Luke

We have shown that performing blood flow restriction (BFR) during low-intensity aerobic exercise can trigger local and systemic hypoalgesia, which is not typically observed with this intensity of exercise. High-pressure BFR triggers greater and comparable hypoalgesia than high-intensity aerobic exercise in the exercising limbs and remote areas of the body, respectively. Performing BFR during low-intensity aerobic exercise activates the opioid and endocannabinoid systems, providing novel insight into potential mechanisms of hypoalgesia with BFR exercise

01 Dec 1987·Trends in Ecology & EvolutionQ1 · BIOLOGY

What else can green monkeys tell us about AIDS?

Q1 · BIOLOGY

Article

Author: A.P. Dobson ; E.R. Carper

Although the development of an HIV vaccine may eventually provide a means of controlling AIDS in developed countries, more immediate and less sophisticated methods are going to have to be developed for use in the rural regions of Africa where AIDS may already have reached epidemic proportions. Evidence from several studies of wild primates suggests that plant secondary compounds may commonly act as control agents for a variety of different pathogens. Although studies of laboratory populations of green monkeys indicate that their resistance to AIDS is likely to be genetic, we argue that it may be worth screening some of the plants eaten by African primates in the hope of coming up with compounds that exhibit suitable anti-viral activity. Any compounds isolated in this way are likely to be much cheaper to manufacture than laboratory-produced drugs and may also have been already screened for unpleasant side-effects.

01 Aug 1987·Journal of Virological MethodsQ4 · MEDICINE

Perspectives of HIV vaccine developments

Q4 · MEDICINE

Review

Author: Reinhard Kurth ; Franz-Josef Ferdinand ; Friedrich Dorner

Human immunodeficiency virus type 1 (HIV-1) may enter the blood stream as free virus or via infected lymphocytes, which poses problems for vaccine development. The classical vaccine designs, attenuated, inactivated, or subunit vaccine will be discussed with regard to HIV. Development of a recombinant subunit vaccine appears to be the most promising approach. Forthcoming results from experiments involving inoculation of chimpanzees should allow evaluation of the feasibility of using a subunit vaccine based on the env-glycoprotein. Also the use of live recombinant vaccinia merits further investigation.

100 Deals associated with HIV vaccine(NuGenerex Immuno-Oncology, Inc.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 1	-	NuGenerex Immuno-Oncology, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

HIV vaccine(NuGenerex Immuno-Oncology, Inc.)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation